MICHAEL B. SHIMKIN; STACY R. METTIER, F.A.C.P.; HOWARD R. BIERMAN
Leukemia was established as a distinct clinical entity in the middle of the Nineteenth Century. As Forkner1 notes in his monograph a hundred years later, "We know almost nothing about its cause or its specific treatment."
Potassium arsenite, radiation and benzol were known by 1915 to produce marked clinical remissions in myelocytic leukemia. During the past four years, three additional agents—ethyl carbamate, the amine mustards, and perhaps the antifolic acid compounds—have been reported to effect distinct clinical improvement in the course of the disease.2
Adequate analyses of the final results of such therapy, in terms of longevity of patients with
MICHAEL B. SHIMKIN, STACY R. METTIER, HOWARD R. BIERMAN. MYELOCYTIC LEUKEMIA: AN ANALYSIS OF INCIDENCE, DISTRIBUTION AND FATALITY, 1910-1948(MYELOCYTIC LEUKEMIA: AN ANALYSIS OF INCIDENCE, DISTRIBUTION AND FATALITY, 1910-1948*). Ann Intern Med. 1951;35:194–212. doi: 10.7326/0003-4819-35-1-194
Download citation file:
Published: Ann Intern Med. 1951;35(1):194-212.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use